Delta4

The AI engine Fit Assessment

Beta

Delta 4 effectively utilizes machine learning for drug discovery, identifies new patterns in drug-disease relationships, and expands therapeutic options through drug repurposing.

Blurb

Delta 4 is a biotech startup driving the forefront of digital drug discovery and development.

HQ Location

Austria

Founded

2019

Employees

1 - 10

Total funding raised

Not available

Last Funding Event

Series A, April 7, 2021

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Drug Repurposing
  • Drug Discovery Optimization

Operator of a digital drug discovery and development company intended to drive the forefront of digital drug discovery and development. The company's platform leverages a proprietary computational analytics platform, combined with straightforward biomedical testing and clinical validation of candidate drugs, and integrates iterative big data with an artificial intelligence-based in-silico platform and experimental screens, enabling researchers to discover treatments for the most complex and rare diseases and offer them efficient matching of clinical indications and compound/drug effect.